

0001104659-24-1270176-K ProQR Therapeutics N.V. 2024121020241210080516080517080517 0 0001104659-24-127017 6-K 2 20241210 20241210 20241210 ProQR Therapeutics N.V. 0001612940 2834 000000000 1231 6-K 34 001-36622 241537175 ZERNIKEDREEF 9 LEIDEN P7 2333 CK 31 88 166 7000 ZERNIKEDREEF 9 LEIDEN P7 2333 CK ProQR Therapeutics B.V. 20140708 6-K 1 tm2430547d1_6k.htm FORM 6-K Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORMÂ 6-K Â Report of Foreign Private Issuer Pursuant to RuleÂ 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Â For the month of DecemberÂ 2024 Â Commission File Number: 001-36622 Â PROQR THERAPEUTICS N.V. Â Zernikedreef 9 2333 CK Leiden The Netherlands Tel: +31 88 166 7000 (Address,Â Including Zip Code, and Telephone Number, Including Area Code, of Registrantâ€™s Principal Executive Offices) Â Indicate by check mark whether the registrant files or will file annual reports under cover of FormÂ 20-F or FormÂ 40-F. Â Form 20-Fâ€”â€”x Â FormÂ 40-Fâ€”â€”Â Indicate by check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(1):â€”â€”Â Indicate by check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(7):â€”â€”Â Â Â Â On December 10, 2024, ProQR Therapeutics N.V. (â€œProQRâ€) issued a press release titled, â€œProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist.â€ A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Â ProQR hereby incorporates by reference the information contained herein into ProQRâ€™s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, and File No. 333-263166). Â Â Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â PROQR THERAPEUTICS N.V. Â Â Date: December 10, 2024 By: /s/ RenÂ© Beukema Â Â RenÂ© Beukema Â Â Chief Corporate Development Officer and General Counsel Â Â Â Â INDEX TO EXHIBITS Â Number Â Description Â Â 99.1 Â Press Release of ProQR Therapeutics N.V. dated December 10, 2024. Â Â EX-99.1 2 tm2430547d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Â ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist Â LEIDEN, Netherlands & CAMBRIDGE, Mass., December 10, 2024 â€” ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomerâ„¢ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQRâ€™s Scientific Advisory Board, where he has played an important role in shaping the Companyâ€™s ADAR-based RNA editing platform. Â Dr. Bealâ€™s decades of research at UC Davis have advanced the scientific communityâ€™s understanding of ADAR-mediated RNA-editing mechanisms and their therapeutic potential. As Chief ADAR Scientist, Dr. Beal will expand on his existing contributions to ProQR by driving the development and optimization of the Companyâ€™s ADAR editing platform, which aims to deliver life-changing treatments for patients with high unmet needs. Â â€œPete has made tremendous impact on ProQR through our long-standing scientific collaboration and his contributions as a member of our Scientific Advisory Board. We are thrilled to now have him join the team in an expanded capacity as Chief ADAR Scientist,â€ said Gerard Platenburg, Chief Scientific Officer of ProQR. â€œHis deep expertise in ADAR biology and RNA chemistry, combined with his strategic insight, will be invaluable as we advance our pipeline of RNA-editing therapies.â€ Â Dr. Beal expressed his enthusiasm for expanding his role at ProQR, stating, â€œI have been deeply impressed by the vision, commitment, and progress of the ProQR team in harnessing RNA editing to address some of the most challenging genetic diseases. Having served on the Scientific Advisory Board, Iâ€™ve seen firsthand the transformative potential of ProQRâ€™s Axiomer RNA editing platform. I am excited to join the company in this new capacity at this pivotal time and to contribute to advancing RNA-editing science toward meaningful therapies for patients.â€ Â In his new role, Dr. Beal will oversee the platform optimization and scientific developments on the design of editing oligonucleotides to further strengthen ProQRâ€™s position as a leader in ADAR mediated RNA-editing innovation, drive preclinical development efforts, and expand the Companyâ€™s therapeutic pipeline. Â Â Â Â Peter A. Beal, PhD, biography Â Peter A. Beal is a Professor in the Department of Chemistry at the University of California at Davis and current Director of the NIH-funded UC Davis Chemical Biology Graduate Program. Research from the Beal laboratory has advanced understanding of the structures and mechanism of action for ADAR enzymes responsible for adenosine to inosine RNA editing in humans. Recently, this knowledge has been applied to the design of guiding oligonucleotides capable of directing ADARs to make edits that correct disease-causing mutations in the transcriptome. Targets include mutations in mRNAs associated with Rett syndrome, Alzheimerâ€™s disease and Parkinsonâ€™s disease. Dr. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. Â About Axiomerâ„¢ Â ProQR is pioneering a next-generation RNA base editing technology called Axiomerâ„¢, which could potentially yield a new class of medicines for diverse types of diseases. Axiomerâ„¢ â€œEditing Oligonucleotidesâ€, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomerâ„¢ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA â€” an Inosine is translated as a Guanosine (G) â€” correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease. Â About ProQR Â ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomerâ„¢, which uses a cellâ€™s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Â Learn more about ProQR at www.proqr.com. Â Â Â Â Forward Looking Statements Â This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as â€œcontinue,â€ "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, express and implied statements regarding Dr. Bealâ€™s expected responsibilities and potential contributions to our therapeutic pipeline, the continued development, optimization and advancement of our Axiomerâ„¢ platform, the therapeutic goal of our Axiomer RNA editing oligonucleotides and product candidates, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking

statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Eli Lilly and the Company; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. Â Â Â Â ProQR Therapeutics N.V. Â Investor contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Peter Kelleher LifeSci Advisors T: +1 617 430 7579 pkelleher@lifesciadvisors.com Â Media contact: Robert Stanislaro FTI Consulting T: +1 212 850 5657 robert.stanislaro@fticonsulting.com Â Â